CHRS

In the past six months, Coherus Oncology's stock has shown volatility, with an average weekly change of 10% over the last three months. As of September 23, 2026, the stock closed at $1.235, having increased by 54.61% over the last 12 months, but with a year-to-date return of -2.46% and a 0.36% decrease in the past month. Key events include a $50 million Follow-on Equity Offering filed on August 30, 2026. On August 5, 2026, the company reported Q2 2026 earnings with an EPS of -$0.22, beating estimates, though the stock price decreased by 2.027% post-announcement; LOQTORZI net sales increased by 15% quarter-over-quarter to $13.6 million, despite Q1 2026 sales being impacted by severe weather and normal seasonality. Additionally, Intas Pharmaceuticals Limited acquired the UDENYCA Franchise from Coherus BioSciences, Inc. for $560 million. There are also ongoing discussions regarding the company's cash position and the potential need for a capital raise within the next 12 months, with usable operating cash estimated at around $105 million post Q1 2026.